TraceLink Releases Amadeus, the First Generative AI Assistant for Accelerating the Digitalization of Supply Networks on the Opus Platform

October 01, 2024 06:00 PM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Trained on a rich set of information from a unified content repository, Opus Orchestration Architects, Solution Designers, Network Administrators, and those simply interested in learning more about TraceLink's solutions are empowered with information in seconds

BOSTON, Oct. 1, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced the launch of Amadeus, an AI Assistant to help users across the supply chain configure and optimize supply networks. Powered by advanced Large Language Model (LLM) algorithms, Amadeus allows users to find answers across a large volume of the TraceLink University educational content ecosystem, including developer resources, educational "how-to" materials, and technical documentation, delivering detailed, accurate responses tailored to their needs.

Whether navigating through extensive resources, searching for specific content, or exploring related topics, Amadeus provides intelligent answers drawn from a knowledge base refreshed on a daily basis. Its advanced search capabilities and context-aware assistance with source URL and citations ensure a smooth, reliable, current, and efficient content discovery process. With instant access to TraceLink University documents, educational whitepapers, case studies, and more, Amadeus delivers quick, within-seconds responses tailored to specific customer use cases, helping users solve complex business problems with confidence.

"With Amadeus, we are offering a powerful way for customers to engage with the wealth of knowledge within TraceLink University," said Shabbir Dahod, President and CEO at TraceLink. "By integrating generative AI and LLMs with our extensive content library, Amadeus helps users to quickly find the information they need to optimize their supply chain operations. This is just the beginning of how TraceLink aims to harness AI to further transform supply chain management in the future."

Amadeus' AI functionality is further enriched by its robust safeguards. Built-in guardrails and alignment with OpenAI's safety protocols verify that responses are relevant and accurate, eliminating AI hallucinations and keeping users on track. With these AI safety features built into Amadeus, users receive the most applicable and trusted answers, helping them make informed decisions in real-time. Looking forward, Amadeus will securely integrate content from customers' own orchestration networks, thereby enabling a powerful AI-driven experience on top of end-to-end supply chain network intelligence to leverage predictions to drive business results.

Learn more about TraceLink's Opus Magnum release, the only no-code network digitalization platform designed to democratize access to end-to-end supply chain integration and orchestration.

See Opus Magnum live at FutureLink Barcelona 2024, the only thought-leadership, education, and networking event for life sciences and healthcare leaders needing critical intelligence and better collaboration across supply chain relationships, from October 2-4, 2024. With keynotes headlined by the industry's top thought leaders, a full day of TraceLink University educational sessions, three orchestration tracks led by customers and solution partners, and an immersive product and solution exhibition, this year's FutureLink will focus on the end-to-end digitalization of your supply chain to link your enterprise systems and processes to the network. Register now.

About TraceLink:

TraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.